

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

Engaging Professor Saibal Kar as External Consultant

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company recently entered into a consultant agreement with Saibal Kar, MD, FACC, FSCAI (“**Dr. Saibal Kar**”) as our exclusive consultant to advise the research and development of our Mitral Transcatheter Edge to Edge Repair project (“**Peijia TEER**”, or “**Project Gemini**”) and to advise the Company in general. During the term and a certain period after the termination of the agreement, he will not work with any other Chinese entity that competes with the Company. Peijia TEER is a transcatheter mitral repair therapy aiming to treat mitral regurgitation patients. The project is undergoing chronic animal testing.

Dr. Saibal Kar is currently a clinical professor in Medicine and director of Structural Heart Disease Intervention and Clinical Research at David Geffen School of Medicine UCLA, California. He is a world leading doctor well-known for his research and achievement in the field of structured heart therapies, particularly in mitral repair space and the winner of several high caliber awards including Man of the Year Award by Centric Health Group. He also serves as external consultant for various multinational medical device companies such as Medtronic Inc., Boston Scientific, and Abbott Vascular. Dr. Saibal Kar also worked as a principal investigator in multicenter studies and randomized studies for MitraClip.

SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, September 6, 2021

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, and Mr. Wai Ming Yip as independent non-executive Directors.